Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T CellsAaron P. Rapoport, Carl H. June, Nicole A. Aqui et al.|Clinical Cancer Research|2014Cited by 123
Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid LeukemiaIvana Gojo, Douglas D. Ross, Ming Tan et al.|Clinical Cancer Research|2013Cited by 49
A prediction model for distinguishing lung squamous cell carcinoma from adenocarcinomaHui Li, Feng Jiang, Zhengran Jiang et al.|Oncotarget|2017Cited by 25
Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-CellsAaron P. Rapoport, Carl H. June, Ling Cai et al.|Blood|2012Cited by 5
Supplementary Table 1 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T CellsAaron P. Rapoport, Carl H. June, Nicole A. Aqui et al.|Unknown|2023Cited by 0